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I.  INTRODUCTION
Over her lifetime, a woman has a one in nine chance of being di-
agnosed with breast cancer.1  Breast cancer is one of the most preva-
lent forms of cancer and is a leading cause of cancer-related death
among American women.2  As Congress begins a new legislative ses-
sion, it has the opportunity to pass legislation that would enable
women who need experimental treatment programs to combat breast
cancer to challenge their insurance company’s denial of coverage.3
Breast cancer testimonials in magazines, newspapers, and on televi-
sion talk shows demonstrate that these reforms are both welcome and
necessary.4
Recently, women have successfully lobbied Congress to pass several
key pieces of legislation specifically designed to benefit women with
                                                                
1. See Denise S. Wolf, Comment, Who Should Pay for “Experimental” Treatments? Breast Cancer
Patients v. Their Insurers, 44 AM. U. L. REV. 2029, 2031 (1995) (noting the prevalence of breast
cancer among American women).
2. See Cancer Incidence in the United States, SAPIENT HEALTH NETWORK BREAST CANCER
SERVICE 1 (visited Jan. 12, 1998) <http://www.shn.webmd.com/index.html>.  Breast cancer
rates in the United States are among the highest in the world.  See Celia Byrne, Risk Factors,
SAPIENT HEALTH NETWORK BREAST CANCER SERVICE 1 (visited Jan. 14, 1998)
<http://www.Sapient Health Network.net>.  Sapient Health Network provides a website on
women’s health issues.  A large portion of the site includes comprehensive information on
breast cancer and many other health issues affecting women.  The site includes everything from
diagnosis to treatment and provides a support system for women dealing with a breast cancer
diagnosis.  The site enables women to connect with other women who are facing the same fears
and problems.  Id.
3. See generally Patient Access to Responsible Care Act of 1997, H.R. 1415, 105th Cong.
(1997) (“PARCA”) (amending Public Health Service Act (“PHSA”) and the Employee Retire-
ment Income and Security Act of 1974 (“ERISA”)); Responsibility in Managed Care Act of 1997,
H.R. 2960, 105th Cong. (1997) (“RMCA”) (amending the ERISA).  At the time this paper was
being written, PARCA and RMCA were referred to Committee for consideration.  As of the time
of publication, the 105th Congress failed to consider either of these bills.  Rep. Charles Norwood
(R-Ga.), who introduced and chaperoned the Bills, plans to renew his push for patient protec-
tion in the 106th Congress.  See Patient’s Bill of Rights All But Dead As 105th Congress Heads into Final
Days, BNA Health Care Daily  191 (Oct. 2, 1998).
4. See, e.g., Tamera Eberlein, The Scariest Health Care News for Women This Year: Cost Cutting
by Insurance Companies May Have an Enormous Impact on Health and Well-Being, REDBOOK,  June 1,
1997, at 112 (noting that on average, women’s health care costs more than men’s, creating a
problem for managed health care); Diane Lange, Treating Breast Cancer: More Information, More
Options, SAN DIEGO UNION & TRIB., July 4, 1997, at E16 (discussing options for women diag-
nosed with breast cancer); CNN & Company: Should Americans Stay Young at All Costs? (CNN tele-
vision broadcast, Jan. 14, 1998) (discussing a woman’s need for support while dealing with
breast cancer).
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breast cancer.5  Legislation proposed in the House of Representatives,
if drafted properly, would compliment this series of legislation de-
signed to benefit breast cancer victims.  This Comment demonstrates
how these two proposals, the Responsibility in Managed Care Act6
(“RMCA”) and the Patient Access to Responsible Care Act7
(“PARCA”), will restore the right of consumers in self-insured plans
to sue their health insurance providers under state law when the
plan’s medical decisions result in injury or death. This Comment also
highlights the inadequacies of the two proposed pieces of legislation.
Ultimately, this author recommends that these bills be moved to the
floor of Congress, debated and enacted in a form similar to the origi-
nal drafts.8
Part II discusses the incidence of breast cancer among women9 and
describes the current treatment options for women.10  Part II explains
a controversial new treatment regime, high-dose chemotherapy –
autologous bone marrow transplant (“HDC-ABMT”).11  Part II focuses
on the insurance industry’s response to this new form of treatment12
and discusses the criteria that insurance providers use in making cov-
                                                                
5. See, e.g., Stamp Out Breast Cancer Act, H.R. 1585, 105th Cong. (1997) (proposing “to
allow postal patrons to contribute to funding for breast cancer research through the voluntary
purchase of certain specialty issued United States postage stamps”); Breast Cancer Screening
Act of 1997, S. 90, 105th Cong. (1997) (requiring studies and guidelines for breast cancer
screening for women ages 40-49); Breast Cancer Patient Protection Act of 1997, S. 143, 105th
Cong. (1997) (requiring minimal hospital stay following mastectomy or lymph node dissection
and prohibiting providers from denying women eligibility, or continued eligibility, to enroll or
to renew coverage under the terms of their insurance plans); Breast Cancer Early Detection Act
of 1997, H.R. 418, 105th Cong. (1997) (amending Title XVIII of Social Security Act to provide
for coverage of annual screening mammography under Part B of Medicare program for women
age 65 or older); Women’s Health and Cancer Rights Act of 1997, H.R. 616, 105th Cong.
(1997) (requiring coverage for minimal hospital stays for mastectomies and lymph node dissec-
tions, reconstructive surgery following mastectomies, and secondary consultations); Expression
of Support for the Goals of National Mammography Day, H.R. Res. 235, 105th Cong. (1997)
(expressing support for goals of National Mammography Day); Resolution Expressing the Sense
of the Senate that Individuals Affected by Breast Cancer Should Not Be Alone in Their Fight
Against the Disease, S. Res. 85, 105th Cong. (1997) (expressing sense of the Senate that women
suffering from breast cancer need support); Women’s Health Equity Act of 1991, H.R. 1161,
102d Cong. (1991) (promoting greater equity in delivery of health care services to America’s
women through expanded research on women’s health issues, improved access to health care
services, and disease prevention). See generally Keelyn Friesen, Comment, Non-Passage of the
Women’s Health Equity Act: Inaction May Lead to Cancerous Results, 14 HAMLINE J. PUB. L. & POL’Y
243, 251-55 (1993) (explaining Women’s Health Equity Act and potential public policy ramifi-
cations of Congress’ failure to pass the proposed Act).
6. H.R. 2960, 105th Cong. (1997).
7. H.R. 1415, 105th Cong. (1997).
8. See infra Part VI.
9. See infra Part II.
10. See infra Part II.
11. See infra Part II.
12. See infra Part III.
3
Anastasio: Legislative Developments in the Regulation of Insurance Coverage:
Published by Digital Commons @ American University Washington College of Law, 1998
58 JOURNAL OF GENDER, SOCIAL POLICY & THE LAW [Vol. 7:55
erage determinations.13  Part III discusses the role the judiciary typi-
cally plays in reviewing coverage determination cases between an in-
surer and an insured.14  Part IV addresses the role played by the Em-
ployee Retirement Income and Security Act of 197415 (“ERISA”) in
affecting a woman’s ability to compel her insurance provider to pro-
vide coverage for HDC-ABMT.16  Part IV further includes a detailed
discussion of the ERISA’s operative provisions and the judicial re-
sponses it has engendered.17  Part V analyzes the two proposed pieces
of legislation that appear to eliminate ERISA’s preemption prob-
lems,18 and suggests that ERISA’s preemption provisions need more
than just procedural changes to afford women a greater ability to
challenge an insurer’s coverage decision.19  Part VI concludes that
substantive changes are needed to provide women with greater access
to the courts so they may be more successful in challenging insurance
companies’ decisions.20
II. A DISCUSSION OF BREAST CANCER FROM DIAGNOSIS TO TREATMENT
A. Diagnosis
Breast cancer is the second-most common cancer, and causes the
majority of cancer deaths among American women.21  Breast cancer
progresses through four distinct stages:
The disease of breast cancer is classified into four stages accord-
ing to the extent of the disease.  In Stage I, the solid tumor is
typically less than one inch thick and is considered small.  By
Stage II, the tumor is larger, approximately one to two inches,
and the cancer has spread to the auxiliary lymph nodes.  In
Stage III, the tumor is greater than two inches and adheres to
the chest wall.  Finally, by Stage IV, the cancer has ‘metasta-
sized,’ or spread to other organs or parts of the body.22
From 1973 to 1991, the incidence of invasive breast cancer in the
                                                                
13. See infra Part III.
14. See infra Part III.
15. 29 U.S.C. §§ 1001-1461 (1994).
16. See infra Part IV.
17. See infra Part IV.
18. See infra Part V.
19. See infra Part V.
20. See infra Part VI.
21. See Byrne, supra note 2, at 1 (noting that, after skin cancer, breast cancer is the most
common form of cancer).
22. Jessica L. Basso, Note, “Experimental” Chemotherapy Treatment for Advanced State Breast
Cancer: Judicial Interpretation of Insurance Policy Coverage, 1 DEPAUL J. HEALTH CARE L. 105, 106
(1996) (internal citations omitted).
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